PharmAsia News Notable Notes: Kotak Initiates Coverage Of Five Indian CMO, CRO Firms
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country
You may also be interested in...
PharmAsia News Notable Notes: CRO/CMO Divis Labs Has “Maximum Upside Potential” In India
NEW DELHI - Kotak Institutional Equities has raised its price target for Hyderabad, India-based Divis Laboratories citing growing contract research and manufacturing as well as generic sales
PharmAsia News Notable Notes: CRO/CMO Divis Labs Has “Maximum Upside Potential” In India
NEW DELHI - Kotak Institutional Equities has raised its price target for Hyderabad, India-based Divis Laboratories citing growing contract research and manufacturing as well as generic sales
PharmAsia News Notable Notes: India’s Sun, Dishman Price Targets Raised By Citigroup, Dr Reddy’s Maintained As Hold
NEW DELHI - Following fourth quarter earnings, Citigroup Global Markets hiked the price target for India's Sun and Dishman pharmaceutical companies citing strong and robust guidance and maintained a hold rating on Dr Reddy's saying management needed to present more clarity